Scientific data regarding intravenous iron supplementation in peritoneal dialysis (PD) patients are scarce. In attempting to administer the minimum monthly IV iron dose that could improve erythropoiesis, we wanted to assess the safety and efficacy of monthly maintenance intravenous administration of 100 mg iron sucrose in PD patients.
In a 9-month prospective study, all clinically stable PD patients received intravenously 200 mg of iron sucrose as a loading dose, followed by monthly doses of 100 mg for five consecutive months. Levels of hemoglobin (Hb), ferritin, transferrin saturation (TSAT), reticulocyte hemoglobin content (CHr) and C-reactive protein (CRP) were measured before each administration and 3 months after the last iron infusion. Also, doses of concurrent erythropoietin administration were recorded.
Eighteen patients were eligible for the study. Mean levels of Hb and ferritin increased significantly (from 10.0 to 10.9 mg/dL, p = 0.01 and from 143 to 260 ng/mL, p = 0.005), as well as the increase in TSAT levels approached borderline significance (from 26.2 to 33.1%, p = 0.07). During the 6 months of iron administration, the erythropoietin dose was reduced in five patients and discontinued in one. During the 3 months following the last iron infusion, three of them again raised the erythropoietin dose to previous levels. None of the patients experienced any side effects related to IV iron administration.
A monthly maintenance intravenous dose of 100 mg iron sucrose may be a practical, effective, and safe in the short term, treatment of anemia in PD patients resulting in improved hemoglobin levels, iron indices, and erythropoietin response.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Pandey R, Daloul R, Coyne DW (2016) Iron treatment strategies in dialysis-dependent CKD. Semin Nephrol 36(2):105–111
Li H, Wang SX (2008) Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int 28(2):149–154
Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM (2001) A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients. Nephrol Dial Transpl 16(9):1879–1884
Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D et al (2013) Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transpl 28(6):1346–1359
Liu H, Yao Y, Cao Y, Yang X, Huang B, Han X et al (2015) Anemia management trends in patients on peritoneal dialysis in the past 10 years. Int J Clin Exp Med 8(10):18050–18057
Wetmore JB, Peng Y, Monda KL, Kats AM, Kim DH, Bradbury BD et al (2015) Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis. Am J Nephrol 41(4–5):354–361
Del Vecchio L, Locatelli F (2017) Clinical practice guidelines on iron therapy: a critical evaluation. Hemodial Int 21:S125–S131
Robinson BM, Larkina M, Bieber B, Kleophas W, Li Y, Locatelli F et al (2017) Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). BMC Nephrol 18(1):330
Moniem KA, Bhandari S (2007) Bolus intraperitoneal iron versus intravenous iron in peritoneal dialysis patients: a prospective study. Transfus Altern Transfus Med 9(2):101–107
Singh H, Reed J, Noble S, Cangiano JL, Van Wyck DB (2006) Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin J Am Soc Nephrol 1(3):475–482
Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Oreopoulos D (2001) Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharine in peritoneal dialysis patients. Perit Dial Int 21(3):290–295
Ahsan Ν (1998) Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 9(4):664–668
Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A (1996) Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72(3):413–417
Richardson D, Bartlett C, Jolly H, Will EJ (2001) Intravenous iron for CAPD populations: proactive or reactive strategies? Nephrol Dial Transpl 16(1):115–119
Zager RA (2005) Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 68(4):1533–1542
Agarwal R, Vasavada N, Sachs NG, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65(6):2279–2289
Vychytil A, Haag-Weber M (1999) Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl 69:S71–S78
Dittrich E, Schillinger M, Sunder-Plassmann G, Hörl WH, Vychytil A (2002) Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients. Perit Dial Int 22(1):60–66
Agarwal R, Davis JL, Smith L (2008) Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol 3(1):98–104
Domrongkitchaiporn S, Jirakranont B, Atamasrikul K, Ungkanont A, Bunyaratvej A (1999) Indices of iron status in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 34(1):29–35
Conflict of interest
The authors have declared no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mitsopoulos, E., Lysitska, A., Pateinakis, P. et al. Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients. Int Urol Nephrol 52, 387–392 (2020). https://doi.org/10.1007/s11255-019-02362-4
- Transferrin saturation